PRO measure | Placebo (n = 107) | Adalimumab (n = 208) | Overall F valuea | P valuec |
---|---|---|---|---|
BASDAI, 0–10 cm | -1.0 ± 0.23 | -2.8 ± 0.17 | 30.30b | < 0.001 |
BASFI, 0–10 cm | -0.5 ± 0.19 | -2.0 ± 0.14 | 23.14b | < 0.001 |
SF-36 PCS, 0–50 | 2.1 ± 0.84 | 7.3 ± 0.59 | 24.56b | < 0.001 |
SF-36 MCS, 0–50 | 2.1 ± 0.95 | 3.7 ± 0.67 | 42.05b | 0.181 |
Physical Function | 4.1 ± 2.00 | 13.3 ± 1.42 | 19.32b | < 0.001 |
Role–Physical | 10.0 ± 3.51 | 27.5 ± 2.51 | 23.00b | < 0.001 |
Bodily Pain | 7.0 ± 2.03 | 20.7 ± 1.45 | 24.39b | < 0.001 |
General Health | 1.5 ± 1.55 | 8.7 ± 1.11 | 21.89b | < 0.001 |
Vitality | 5.8 ± 1.86 | 14.6 ± 1.33 | 21.33b | < 0.001 |
Social Function | 5.0 ± 2.11 | 12.6 ± 1.51 | 34.86b | 0.003 |
Role–Emotional | 5.0 ± 3.55 | 15.6 ± 2.51 | 77.42b | 0.015 |
Mental Health | 4.8 ± 1.54 | 5.9 ± 1.11 | 30.43b | 0.551 |
ASQOL, 0–18 | -1.1 ± 0.40 | -3.5 ± 0.28 | 17.28b | < 0.001 |